Metformin attenuates symptoms of osteoarthritis: role of genetic diversity of Bcl2 and CXCL16 in OA

Table 4 The KOOS scores pre and post-treatment in metformin and placebo groups

KOOS scales	Mean ± SD		Pm	Mean ± SD		Pp	P mp
	Metformin (N = 44)		Pm	Placebo (N = 44)		Pp	P mp
	Pre-treatment	Post-treatment		Pre-treatment	Post-treatment		Post-treatment
Total	52.7 ± 18.4	65.8 ± 19.8	0.0001	52.7 ± 19.0	51.0 ± 18.2	0.055	0.0001
Symptoms	77.7 ± 14.9	78.7 ± 17.4	0.664	75.6 ± 17.3	73.6 ± 17.5	0.014	0.166
Pain	54.9 ± 18.8	70.8 ± 19.1	0.0001	51.8 ± 19.0	50.5 ± 19.0	0.07	0.0001
ADL	55.7 ± 20.8	72.9 ± 19.2	0.0001	55.1 ± 24.1	56.3 ± 20.4	0.362	0.0001
Sport/Rec	35.1 ± 29.0	53.0 ± 31.3	0.0001	37.8 ± 28.6	32.3 ± 23.7	0.001	0.0001
QOL	39.6 ± 20.3	53.6 ± 26.0	0.002	41.1 ± 20.5	41.6 ± 21.6	0.472	0.003

Pm, the calculated P value between the pre and post-treatment times in the metformin group; Pp, the calculated P value between the pre and post-treatment in placebo group; P mp, the calculated P value between post-treatment times of the metformin and placebo groups

ISSN: 1478-6362